Agarigen, Inc. is a privately held Delaware corporation dedicated to harnessing the remarkable biological productivity of the common mushroom (Agaricus bisporus) for the manufacture of biologics (biopharmaceuticals, therapeutic proteins). Compared to conventional cell culture technologies, Agarigen’s Mushroom-made Pharmaceuticals (MMP™) system can deliver high-quality therapeutics at a fraction of the current manufacturing cost, time, and start-up capital. The favorable economy, rapid growth cycle, and high biomass output of the mushroom make the MMP™ system the most efficient and effective approach to the manufacture of biologics.
|